The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
A microbiome company specialising in prebiotics reports good effects in health of covid sufferers who have comorbidities.
https://investors.kaleido.com/news-releases/news-release-details/kaleido-biosciences-reports-positive-results-non-ind-study
These kind of results help the whole microbiome sector.
Is there an RNS or is that a theory?
I think they also have a massive amount of cash, don't quote me on that.
Injecting the tumour is something to do with turning a "cold" tumour "hot", basically infiltrating the cancer and making it visible to the immune system, at least in theory. Injected once a week initially and then every 21 days.
@Wigwammer Artificially modified bacteria, similar approach to 4D pharma.
Yes, Synlogic are building their own artificial bacteria rather than discovering them like 4D does. They also inject the tumour directly in their oncology trial so taking a different approach.
They don't actually know what the highest possible dosage is hence the different dosage cohorts. Makes sense to keep increasing the dosage to find the optimal level.
Have you guys seen Synlogic's oncology data? Preclinical data looks insanely strong. They also say they have stable disease in two people taking just the biotherapeutic without any checkpoint inhibitor.
Phone Interactive Investor and ask them, sounds more like a software bug.
Agreed, I did my DD on IMM and it looked like the drug had no benefit for Lupus. Surprised they resurrected the trial and even more surprised that some people on that board claim to have £200K invested, genuinely hope it pays off.
Thanks ontarget.
In the end, WhaleWisdom.com is the best I could find although the data is a bit patchy:
https://whalewisdom.com/filer/octopus-investments-nominees-limited#tablse_positions_link
https://whalewisdom.com/filer/richard-griffiths#tablse_positions_link
Does anyone know of a free website where I can view the TR1 holdings of Octopus Investments and Richard Griffiths?
£572K trade after hours.
I've got to say Moneymunch, I've been looking for information as a potential new investor and every time I come to LSE or ADVFN, you've buried all opinions in lengthy spam posts.
Please post using the #EVG hashtag on Twitter instead of shutting down all conversation.
@Sangijuelas1 I think you are a shorter, you are saying very strange things.
Looks to me like a TR1 still clearing their holding.
Day traders might regret selling before seeing the pre-market of 4D's US merger ticker LOAC.
Just a heavily manipulated stock, Citadel control anywhere the share price goes. The system is heavily rigged in favour of hedge funds and they love shorting 4D Pharma stock while news is pending.
It produces the produces the bacteria used in clinical trials....
- 4D also have their own manufacturing facilities which is very important.
- 4D have over 1000 patented strains of bacteria.
Plenty of potential news for new investors to get excited about.
- NASDAQ listing expected Q1. Latest investor presentation says EARLY Q1, we're just waiting on the SEC to finish their administrative tasks.
- 4D's competitors on NASDAQ are receiving strong investor interest right now, look at companies like Evelo, Seres and Synlogic.
- In the SITC event presentation, 4D stated they would talking to FDA in early 2021 about possible accelerated approval or another pathway for their cancer drug due to high unmet need.
- Neurodegeneration and/or autism human trial(s) expected to be announced this year. There is a high unmet need again so potential for FDA accelerated approval pathway.
- Covid trial only needs 90 participants, we could hear something soon.
- Blautix is the first therapy to potentially treat IBS-D and IBS-C, we're waiting for Phase 3 news.
- A second-generation cancer therapy is in development.
- Merck selected 4D Pharma's Micro Rx platform above everyone else to enhance their vaccines. Micro Rx is a world-leading platform that many other pharma companies might want to use.
- 4D's cancer drug Mrx0518 is compatible with many other cancer therapies, we could see further collaboration with big pharma companies.
- 4D have drugs in their pipeline to potentially address autoimmune disorders.
- 4D Pharma staff are excited about the asthma trial.
4D are concentrating on diseases like treatment-refractive cancers, neurogenerative disorders, autoimmune disorders, IBS & autism which all have very high unmet need. Using gut bacteria to treat disease is a new frontier in medicine.
Disclaimer: I wrote this from memory, it may contain errors. None of this is investment advice, please do your own research and make your own investment decisions.